Lamivudine and Dermatitis allergic - a phase IV clinical study of FDA data


Dermatitis allergic is found among people who take Lamivudine, especially for people who are female, 30-39 old, have been taking the drug for 6 - 12 months.

The phase IV clinical study analyzes which people take Lamivudine and have Dermatitis allergic. It is created by eHealthMe based on reports of 16,771 people who have side effects when taking Lamivudine from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.

On May, 22, 2022

16,771 people reported to have side effects when taking Lamivudine.
Among them, 11 people (0.07%) have Dermatitis allergic.

What is Lamivudine?

Lamivudine has active ingredients of lamivudine; zidovudine; nevirapine. It is often used in hiv infection. eHealthMe is studying from 16,808 Lamivudine users for its effectiveness, alternative drugs and more.

What is Dermatitis allergic?

Dermatitis allergic (inflammation of the skin due allergic reaction) is found to be associated with 1,108 drugs and 677 conditions by eHealthMe.

Number of Lamivudine and Dermatitis allergic reports submitted per year:

Could Lamivudine cause Dermatitis allergic?

Time on Lamivudine when people have Dermatitis allergic *:

  • < 1 month: 0.0 %
  • 1 - 6 months: 0.0 %
  • 6 - 12 months: 50 %
  • 1 - 2 years: 0.0 %
  • 2 - 5 years: 50 %
  • 5 - 10 years: 0.0 %
  • 10+ years: 0.0 %

Gender of people who have Dermatitis allergic when taking Lamivudine *:

  • female: 72.73 %
  • male: 27.27 %

Age of people who have Dermatitis allergic when taking Lamivudine *:

  • 0-1: 9.09 %
  • 2-9: 27.27 %
  • 10-19: 0.0 %
  • 20-29: 0.0 %
  • 30-39: 54.55 %
  • 40-49: 0.0 %
  • 50-59: 0.0 %
  • 60+: 9.09 %

Common drugs people take besides Lamivudine *:

  1. Efavirenz: 5 people, 45.45%
  2. Zidovudine: 4 people, 36.36%
  3. Tenofovir Disoproxil Fumarate: 3 people, 27.27%
  4. Folic Acid: 3 people, 27.27%
  5. Didanosine: 3 people, 27.27%
  6. Ritonavir: 3 people, 27.27%
  7. Sustiva: 3 people, 27.27%
  8. Isentress: 3 people, 27.27%
  9. Videx: 3 people, 27.27%
  10. Abacavir Sulfate: 3 people, 27.27%

Common side effects people have besides Dermatitis allergic *:

  1. Fatigue (feeling of tiredness): 5 people, 45.45%
  2. Diarrhea: 4 people, 36.36%
  3. Rash Maculo-Papular (red area on the skin that is covered with small confluent bumps): 3 people, 27.27%
  4. Itching: 3 people, 27.27%
  5. Headache (pain in head): 3 people, 27.27%
  6. Hair Loss: 3 people, 27.27%
  7. Erythema Nodosum (skin inflammation that results in reddish, painful, tender lumps most commonly located in the front of the legs below): 3 people, 27.27%
  8. Opportunistic Infection (a microorganism that normally does not cause disease but becomes pathogenic when the body's immune system is impaired and unable to fight): 3 people, 27.27%
  9. Pneumocystis Jiroveci Pneumonia (fungal infection of the lungs): 3 people, 27.27%
  10. Drug Exposure During Pregnancy: 3 people, 27.27%

Common conditions people have *:

  1. Tuberculosis (a bacterial infection by mycobacterium tuberculosis): 1 person, 9.09%
  2. Retroperitoneal Fibrosis (a rare disorder that occurs when extra fibrous tissue forms in the area behind the stomach and intestines): 1 person, 9.09%
  3. High Blood Pressure: 1 person, 9.09%
  4. Gout (uric acid crystals building up in the body): 1 person, 9.09%
  5. Diabetes: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Lamivudine and have Dermatitis allergic?

Check whether Dermatitis allergic is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

Alternative drugs to, pros and cons of Lamivudine:

Dermatitis allergic treatments and more:

COVID vaccines that are related to Dermatitis allergic:

How severe was Dermatitis allergic and when was it recovered:

Expand to all the drugs that have ingredients of lamivudine; zidovudine; nevirapine:

Common drugs associated with Dermatitis allergic:

All the drugs that are associated with Dermatitis allergic:

Common conditions associated with Dermatitis allergic:

All the conditions that are associated with Dermatitis allergic:

How the study uses the data?

The study uses data from the FDA. It is based on lamivudine; zidovudine; nevirapine (the active ingredients of Lamivudine) and Lamivudine (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).


WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: